Last reviewed · How we verify
KarX-EC
KarX-EC is an extended-release formulation designed to improve the pharmacokinetic profile and therapeutic delivery of its active component.
At a glance
| Generic name | KarX-EC |
|---|---|
| Also known as | BMS-986519, Xanomeline Enteric-coated, Xanomeline enteric capsules, BMS-986519 |
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action for KarX-EC is not publicly disclosed in available sources. As a Phase 3 candidate from Bristol-Myers Squibb, it represents an investigational therapy in development, but specific molecular targets and mechanistic details remain proprietary or under investigation.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively (PHASE3)
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (PHASE3)
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) (PHASE3)
- A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) (PHASE3)
- A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) (PHASE3)
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism (PHASE3)
- A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KarX-EC CI brief — competitive landscape report
- KarX-EC updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI